Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyLudwig Kappos, Rupert Sandbrink, Xavier Montalbán et al.|The Lancet|2007Cited by 502
Lack of Association between Antimyelin Antibodies and Progression to Multiple SclerosisJens Kühle, Rupert Sandbrink, Frederik Barkhof et al.|New England Journal of Medicine|2007Cited by 258
Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1bCH Polman, Bernard M.J. Uitdehaag, Xavier Montalbán et al.|Journal of Neurology|2007Cited by 75